Critics attack transfer of responsibility for drugs in EuropeBMJ 2014; 349 doi: https://doi.org/10.1136/bmj.g5700 (Published 16 September 2014) Cite this as: BMJ 2014;349:g5700
- Rory Watson
The decision by the incoming European Commission president, Jean-Claude Juncker, to transfer responsibility for health technology, pharmaceuticals, and the European Medicines Agency over the next five years away from the commission’s health directorate to its industry counterpart has provoked an outcry from public health professionals.
The transfer reverses the decision by Juncker’s predecessor, Jose Manuel Barroso, five years ago to move the drugs and medical devices brief and the medicines agency away from the industry directorate to health. The U turn has prompted fears that business considerations will weigh more heavily than medical ones when future legislation or drug authorisation is being considered.
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial